Saving Tranquility Base

1043
Children's science book shortlists
Open Data: Crediting a Culture of Cooperation
ALTHOUGH THE QUESTION OF WHO PAYS FOR
open data is important ("Who will pay for public access to research data?", F. Berman and V. Cerf, Policy Forum, 9 August, p. 616), a greater challenge lies in implementing the institutional and cultural changes required before data from government-sponsored research can be openly shared. The Offi ce of Science and Technology Policy (OSTP) has ordered U.S. federal agencies to formulate plans to share federally funded science data (1) . This reflects a fundamental shift in the social contract between scientists and society. While seeking to strengthen science, the order also seeks better use of data to promote economic innovation, improve crossdisciplinary efforts, and address "grand challenge" societal problems such as global climate change and urban violence.
The OSTP memo correctly notes that public availability of atmospheric data enabled commercial weather services and severe weather prediction. Yet many data, tools, and models in the geosciences are held by a mix of individual investigators, national data centers, university-based initiatives, and commercial labs, embedded in institutional arrangements that actively reward holding onto data and maximizing individual outcomes in a competitive environment. NSF's EarthCube project, a long-term strategic initiative to build the cyber infrastructure for integrating data, tools, and models in the geosciences, illustrates the challenges and benefi ts of community engagement and institutional alignment (2) .
The push for open data goes beyond the question of who pays. It challenges science to create a more cooperative culture that aligns credit and rewards with sharing data, tools, and models.
The More Parasites, the Better?
S. ALTIZER ET AL.'S REVIEW "CLIMATE CHANGE AND INFECTIOUS DISeases: From evidence to a predictive framework" (2 August, p. 514) suggests that increased temperatures will favor several attributes of virulent pathogens that will adversely affect host health. Altizer et al. predict a decline in parasite biodiversity but overlook an important problem: This loss could have dire consequences to ecosystems.
Parasite diversity benefi ts ecosystems by regulating host population dynamics, increasing connectivity and stability in food webs (1) and decreasing community-level disease risk. For example, increased parasite richness reduced transmission of the virulent trematode Ribeiroia to amphibian hosts by more than 50% (2). This decrease in disease risk may be due to either increased parasite competition within intermediate hosts (2) or antiparasite immune responses increasing immune genetic diversity in hosts (3). Pathogens can also have a mediating effect on interspecifi c competition between shared hosts, as in the case of Anolis gingivinus lizards in the Caribbean, which exclude sister species A. wattsi except when their competitive ability is diminished by the presence of Plasmodium azurophilum (4). Parasites likely mediate such interactions largely through immune costs, with hosts trading off resource use between immune responses and reproduction and growth (5) . Thus, although some virulent parasite populations may increase with climate change, we anticipate that the loss of parasite biodiversity will result in more widespread and unpredictable threats to ecosystem health. We therefore call for further research into parasite ecology and host-parasite coextinctions as tools for quantifying ecosystem vulnerability to climate change. Research data must be hosted somewhere, new biological information must be curated, and services must be managed. All these incur substantial costs. Yet, the research community conventionally expects that access to data should be free. I agree that cultural change is needed. Berman and Cerf, assuming a small data-access fee on par with buying music on the Internet, proposed a broader adoption of the payment model. However, some databases of high community value that have lost their public funding support have had to resort to a subscription model. For example, Human Gene Mutation Database (www.hgmd.cf.ac.uk) and Kyoto Encyclopedia of Genes and Genomes (www.genome.jp/kegg) are now charging about US$3000 to $5000 annually for each academic research group. These prices are substantially more than the cost of subscribing to digital versions of a newspaper or paying for music on iTunes. Precedents such as these suggest that the cost would be unaffordable for some research groups.
How can a mature database remain both fi nancially sustainable and accessible to a broad community of users? Every day, scientists use these databases as starting points for in-depth analysis, learning about the data and deriving incremental fi ndings. Perhaps it is time for the subscription-based databases to adopt a curator reward system in which access fees are reduced in exchange for a certain amount of quality curation. If this model were successful, scientists who were unable to pay could help improve the databases in exchange for continuous access. This could be a win-win economic model for both scientists and database managers.
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Ethics Tests for Trials
IN HIS NEWS & ANALYSIS STORY "CLINICAL trials paused as India adopts new rules" (26 July, p. 327), Y. Bhattacharjee discusses the new regulations put in place to protect clinical trial participants. Ethics committees responsible for approving clinical trial protocols play a key role in participant safety. It should be deemed unethical to enroll patients in a clinical trial that has a low probability of generating meaningful information, no matter how promising a new investigational therapy. Thus, the ethics committee should always critically evaluate clinical trial protocols for their probability of success.
To make sure these evaluations occur, ethics committees should include or consult qualifi ed statisticians. Ethics committees should ensure that clinical study protocols are adequately powered to succeed and that the underlying assumptions used in power calculations are reasonable. Only then should clinical trials be allowed to proceed in India, or the rest of the world.
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